Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc.（APGE）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · APGE · 截至 2025年3月31日
股东结构概览
179
机构持有人数
▲ 16 vs Q4
$2.32B
机构持仓总市值
▼ $304.99M vs Q4
61.90M
总流通股
freeFloat 92.01%
72.19M
13F 申报持股数
▲ 14.31M vs Q4
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
APGE 最大股东 · 机构持仓
Q1 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
OCTAGON CAPITAL ADVISORS LP biological products, (no diagnostic substances) | 10.70M | 18.39% | 18.39% | $14.87B | May 15, 2025 | NEW |
VR ADVISER, LLC biological products, (no diagnostic substances) | 8.49M | 14.59% | 14.59% | $317.31B | May 15, 2025 | — held |
FMR LLC biological products, (no diagnostic substances) | 7.49M | 12.88% | 12.88% | $279.96B | May 12, 2025 | ▼ 5.8K |
WELLINGTON MANAGEMENT GROUP LLP biological products, (no diagnostic substances) | 5.49M | 9.43% | 9.43% | $204.95B | May 13, 2025 | ▲ 968.4K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 2.91M | 5.00% | 5.00% | $108.75B | May 2, 2025 | ▼ 134.1K |
RTW INVESTMENTS, LP biological products, (no diagnostic substances) | 2.71M | 4.66% | 4.66% | $101.32B | May 15, 2025 | — held |
DRIEHAUS CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 2.34M | 4.02% | 4.02% | $87.41B | May 15, 2025 | ▼ 265.7K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.08M | 3.58% | 3.58% | $77.81B | May 9, 2025 | ▼ 15.0K |
FAIRMOUNT FUNDS MANAGEMENT LLC biological products, (no diagnostic substances) | 2.05M | 3.52% | 3.52% | $76.54B | May 15, 2025 | — held |
JANUS HENDERSON GROUP PLC biological products, (no diagnostic substances) | 1.79M | 3.08% | 3.08% | $71.29B | May 15, 2025 | ▲ 658.7K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q1 2025 对比上季度
Q1 2025
22
增持
+5.93M 股4
新建仓
首次建仓18
减持
−2.04M 股0
清仓
完全退出净股数变化（前50家）
+3.89M
+5.93M / −2.04M
净新增持仓人
+8
新建 4 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
APGE 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
4
买入笔数
21
卖出笔数
0.19
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Dambkowski Carl Chief Medical Officer | Jun 3, 2026 | Sale | 5,500 | $78.71 | $432.9K | 205.6K | Form 4 ↗ |
HENDERSON MICHAEL THOMAS Chief Executive Officer | May 13, 2026 | Sale | 18,659 | $82.05 | $1.53M | 1.12M | Form 4 ↗ |
HENDERSON MICHAEL THOMAS Chief Executive Officer | May 13, 2026 | Sale | 1,341 | $82.58 | $110.7K | 1.12M | Form 4 ↗ |
Dambkowski Carl Chief Medical Officer | May 6, 2026 | Sale | 3,700 | $83.92 | $310.5K | 208.8K | Form 4 ↗ |
Dambkowski Carl Chief Medical Officer | May 6, 2026 | Sale | 1,800 | $84.60 | $152.3K | 207.0K | Form 4 ↗ |
Henderson Jane Chief Financial Officer | May 1, 2026 | Sale | 811 | $81.02 | $65.7K | 174.6K | Form 4 ↗ |
Henderson Jane Chief Financial Officer | May 1, 2026 | Sale | 900 | $82.60 | $74.3K | 173.7K | Form 4 ↗ |
Henderson Jane Chief Financial Officer | May 1, 2026 | Sale | 289 | $83.16 | $24.0K | 173.4K | Form 4 ↗ |
Henderson Jane Chief Financial Officer | Apr 16, 2026 | Sale | 2,000 | $90.00 | $180.0K | 175.4K | Form 4 ↗ |
HENDERSON MICHAEL THOMAS Chief Executive Officer | Apr 8, 2026 | Sale | 17,800 | $82.48 | $1.47M | 1.14M | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Apogee Therapeutics, Inc.（APGE）主要由机构投资者持有，机构持股比例约为 100.0%。公司内部人员持股约 7.99%，散户及公众持股约占剩余的 0.00%。
Apogee Therapeutics, Inc. 最大机构股东为 OCTAGON CAPITAL ADVISORS LP，截至 March 31, 2025 持有约 10.70 million 股，占总流通股的 18.39%。
目前共有 179 家机构持有 APGE 股票，合计持仓市值约 $2.32 billion，数据来源为最新 SEC 13F 申报。
常见问题
APGE ownershipApogee Therapeutics, Inc.（APGE）主要由机构投资者持有，机构持股约 100.0%。最大股东为 OCTAGON CAPITAL ADVISORS LP，持股比例 18.39%。内部人员持股约 7.99%。数据来源 SEC Form 13F，截至 March 31, 2025。